{"entity":{"id":"ifm-2009","kind":"trial","name":"IFM 2009","aka":["IFM/DFCI 2009","IFM 2009 trial"],"tldr":"IFM 2009 asked whether a stem cell transplant is still needed when myeloma is treated with modern three-drug therapy; the transplant kept the disease away for longer, though patients lived about as long either way because those who relapsed could be transplanted later.","summary":"The French IFM 2009 trial randomised 700 adults up to 65 with newly diagnosed multiple myeloma to eight cycles of lenalidomide, bortezomib and dexamethasone (RVD), or to three cycles of RVD, high-dose melphalan with autologous stem cell transplant and two further RVD cycles. Both arms received one year of lenalidomide maintenance. The primary endpoint was progression-free survival.\n\nEarly transplant lengthened progression-free survival and produced deeper responses, including more patients with no detectable minimal residual disease, but overall survival was similar because most patients in the RVD-alone arm received a transplant at relapse. The trial, and the parallel DETERMINATION trial in the United States, defined transplant as a component that lengthens remission rather than life in the era of triplet induction, and framed the current question of whether quadruplets and CAR-T can replace it.","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT01191060","url":"https://clinicaltrials.gov/study/NCT01191060"}],"tags":["subtype-trials"],"related":[],"cancers":["myeloma-transplant-eligible","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["lenalidomide","bortezomib","dexamethasone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["michel-attal"],"bottlenecks":[],"keyPapers":["paper-ifm-2009-attal-nejm-2017"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01191060","phase":"3","setting":"Newly diagnosed multiple myeloma in patients up to 65: lenalidomide, bortezomib and dexamethasone (RVD) alone against RVD with early autologous stem cell transplant, both followed by lenalidomide maintenance","sponsor":"Intergroupe Francophone du Myelome (University Hospital Toulouse)","result":"Early autologous transplant after RVD lengthened progression-free survival compared with RVD alone, with similar overall survival at first analysis.","yearReported":2017,"enrolled":700,"outcomes":[]},"route":"/trials/ifm-2009/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}],"person":[{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/"}],"paper":[{"id":"paper-ifm-2009-attal-nejm-2017","kind":"paper","name":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","route":"/key-papers/paper-ifm-2009-attal-nejm-2017/"}]}}